Central Nervous System Toxicity of Chemotherapy

Schlegel U

European Association of NeuroOncology Magazine 2011; 1 (1)
25-29
Central Nervous System Toxicity of Chemotherapy

Uwe Schlegel

Abstract: Cytostatic drugs may exert toxic effects on the central nervous system by various mechanisms and may lead to reversible or irreversible neurologic dysfunction. The clinical symptoms are often self-limiting, but may be acute, dramatic, and sometimes even fatal. Since causative therapeutic measures are limited, the knowledge of risk factors, characteristic clinical symptoms, symptomatic treatment, and monitoring of the affected patients is essential. Eur Assoc Neurooncol Mag 2011; 1 (1): 25–9.

Key words: chemotherapy, neurotoxicity, central nervous system, prevention, therapy

Introduction

Several cytostatic drugs may harm the central nervous system after systemic (intravenous, oral) administration or after topical, ie intrathecal, intraventricular, or intraarterial application. The brain is at particular risk and side effects may present as acute, subacute, or chronic encephalopathy. Seizures, focal symptoms like aphasia or hemiparesis, and cortical blindness may occur as isolated symptoms. These symptoms may present immediately after chemotherapy administration or with delay. Aseptic meningitis is a typical complication of intrathecal therapy, particular drugs can cause cerebellar ataxia, often after a certain cumulative dose has been exceeded. Toxicity to the spinal cord is rare but severe and most frequently it is the result of intrathecal drug administration. Certain antibodies used in oncology, such as rituximab, are associated with an increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic infection with the JC virus as a result of immunosuppression. However, these and other “indirect” CNS complications of chemotherapy will not be addressed here.

Neurotoxic complications of chemotherapy frequently present with characteristic symptoms and need to be separated from other morphologic (ie metastatic), infectious, or metabolic causes of CNS dysfunction in oncology. Complete or partial recovery may frequently be encountered, but irreversible damage and even death are possible as well. Since therapeutic measures are often limited, prevention is necessary and requires knowledge of neurotoxic side effects to ensure careful monitoring of patients at risk. Discontinuation of chemotherapy is often the only method to prevent further CNS toxicity. The frequency of CNS toxicity depends on the drug chosen, on its single and cumulative doses, on the duration of treatment, and on additional risk factors, such as coexisting neurological morbidity. Well-known factors to substantially increase this risk are dose escalation, combination versus monotherapy, high-dose chemotherapy with stem cell transplantation, and irradiation (RT) of the brain, with chemotherapy after RT probably being more harmful than the reverse sequence [1, 2]. Cytostatics most frequently associated with CNS toxicity are methotrexate (MTX), cytarabine (Ara-C), and ifosfamide. Table 1 shows chemotherapy-induced neurotoxic complications and the respective causative agents.

In the following, characteristic clinical pictures and cytostatics with well-known CNS toxicity will be described. Hypotheses with regard to pathogenesis and possible methods of prevention as well as therapy are discussed.

Acute Encephalopathy

Acute encephalopathy develops within a few hours to days after chemotherapy and presents with disorientation, confusion, agitation, and eventually coma. Myoclonic jerks, seizures, and hallucinatory symptoms may occur. The disorder has to be separated from non-convulsive epileptic state, (viral) encephalitis, metabolic disorders, paraneoplastic syndrome, such as limbic encephalitis, and others [2]. Protocols typically associated with acute encephalopathy include methotrexate (MTX), ifosfamide, and rarely others [3, 4] (Table 1).

Methodoxetate

Acute encephalopathy is frequently self-limiting, but may be dramatic or even fatal: a life-threatening acute encephalopathy in a 32-year-old female came to our attention, who was treated for Burkitt lymphoma with 1.5 g/m² MTX intravenously (iv) over 24 hours and 15 mg intrathecally. She was found to be of homozygous allelic state of the G-allele of 5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR) c.2756A>G, which is observed in only approximately 4 % of the general population [5]. MTX-induced leukoencephalopathy and demyelination have been linked to functional polymorphisms in enzymes influencing the methionine-homocysteine pathway so that S-adenosylmethionine (SAM), the only methyl-group donor in the CNS, is reduced [6, 7] and levels of (toxic) homocysteine [8, 9] may be increased. MTX therapy leads to a lack of the folate derivate used as MTR cofactor and thus to reduced MTR activity resulting in a reduction of SAM bioavailability. The G-allele of MTR c.2756A>G may therefore have pronounced the adverse effect of MTX on SAM synthesis and this rare homozygous allelic state might have contributed to the acute MTX-induced encephalopathy in the patient observed [5]. Since oral SAM substitution can revert CNS demyelination in patients with (inborn) SAM deficiency, SAM and folate-derivates may be interesting candidates for treatment of MTX-induced neurotoxicity [5].
**Table 1. Clinical syndromes of CNS toxicity caused by cytostatic drugs**

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Drugs/Chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute (reversible) encephalopathy</td>
<td>Methotrexate (MTX), ifosfamide, paclitaxel, 5-fluorouracil (5-FU), cytosinabinoside (Ara-C), procarbazine, nitrosoureas (high dose), interferon-α, interleukin-2, tamoxifen (high dose), etoposide, VP16 (high dose), steroids, high dose with stem cell transplantation</td>
</tr>
<tr>
<td>Chronic encephalopathy</td>
<td>MTX iv/intrathecally, interferon-α, high-dose polychemotherapies</td>
</tr>
<tr>
<td>Reversible posterior (leuko-) encephalopathy syndrome (PRES)</td>
<td>Cyclosporine, combination therapy including cyclophosphamide, Ara-C, cis-platinum, cyclophosphamide, ifosfamide, vincristine, gemcitabine, other immuno-suppressants</td>
</tr>
<tr>
<td>Multifocal leukoencephalopathy</td>
<td>Capecitabine</td>
</tr>
<tr>
<td>Thrombotic microangiopathy</td>
<td>Mitomycine-C, gemcitabine, cyclosporine</td>
</tr>
<tr>
<td>Cerebral infarctions</td>
<td>MTX, cyclosporine, platinum derivatives</td>
</tr>
<tr>
<td>Cortical blindness</td>
<td>Platinum derivatives, fludarabine (high dose)</td>
</tr>
<tr>
<td>Cerebellar dysfunction</td>
<td>Ara-C, 5-FU, interferon-α, vincristine, cyclosporine</td>
</tr>
<tr>
<td>Seizures</td>
<td>MTX, etoposide, VP16 (high dose), cis-platinum, vincristine, asparaginase, BCNU, dacarbazine, amascrin, busulfan (high dose), cyclosporine, misonidazol, paclitaxel</td>
</tr>
<tr>
<td>Aseptic meningitis</td>
<td>MTX, Ara-C (intrathecally)</td>
</tr>
</tbody>
</table>

**Ifosfamide**

Ifosfamide is another drug known to potentially induce acute encephalopathy, which may be severe and may even cause death: in 10–15% of patients treated with dosages > 1 g/m², disorientation, lethargia, and coma may occur [4]. Non-convulsive epileptic states caused by ifosfamide have been reported [10]. The pathogenesis is not fully understood, however, ifosfamide and its metabolites may interfere with thiamine function and with that of its phosphorylated forms TPP and TTP, while vitamin B₁ levels themselves are not decreased. Thus, prophylaxis with thiamine, 100 mg iv every 4–6 hours, has been proposed for prevention of ifosfamide-induced encephalopathy [11, 12] as has been therapy/prevention with methylene-blue 50 mg 6× per day iv [13]. However, the therapeutic value of these measures was not confirmed by a recent retrospective analysis [14] and remains difficult to interpret since spontaneous recovery is frequent. A risk factor associated with the occurrence of ifosfamide-induced acute encephalopathy is reduced serum albumine [4, 15].

**Subacute Encephalopathy**

Subacute encephalopathy is rare and may develop days to weeks after administration of MTX (iv or intrathecally) or of cis-platinum, presenting as abrupt onset of confusion, seizures, focal signs, and symptoms such as hemiparesis and aphasia [4, 8, 16, 17]. Children are mainly affected [8, 16], but single cases in adults have been reported as well [17]. The mechanism of neurotoxicity is poorly understood: symmetrically hyperintense signals in diffusion-weighted imaging (DWI) and decreased apparent diffusion coefficient (ADC) on magnetic resonance imaging (MRI) paralleled the clinical symptoms in a patient reported and disappeared with their resolution. In the absence of vascular or perfusion changes, these MRI findings have been interpreted as cytotoxic oedema of the white matter but sparing the cerebral cortex [17]. Symptoms may resolve completely, however, lethal outcome has been observed [18]. In children suffering from subacute MTX-induced encephalopathy, dextromethorphan 1–2 mg/kg orally, a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, has been applied to 5 affected children, followed by complete resolution of symptoms [8], but has never been re-evaluated systematically since.

**Chronic Encephalopathy**

Chronic encephalopathy usually starts to develop with a latency of several months to years, is most frequently irreversible and sometimes even progressive. MTX-induced chronic encephalopathy is best known, however, other drugs or polychemotherapies such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) may also cause this complication, however, less frequently [1]. The main risk factor for the development of MTX-induced chronic encephalopathy is whole-brain irradiation [19]. The clinical spectra of chronic encephalopathy range from subtle memory disturbances, disorientation, lack of initiative and apathy to full-blown dementia. No efficient treatment is known. Cerebral imaging shows (often confluent) white matter disease, i.e. leukoencephalopathy, and progressive deep brain atrophy (Figure 1). It is of note, however, that even long-lasting extensive MTX-induced confluent white matter changes may be clinically asymptomatic [20]. High-dose chemotherapy with haematopoetic stem-cell support in patients with breast cancer was reportedly followed by memory disturbances in some of them [21], however, neuropsychometric findings from long-term follow-up are not available.

**Posterior Reversible Encephalopathy Syndrome (PRES)**

PRES is clinically characterised by headache, visual disturbances, such as visual field deficits and cortical blindness, confusion, seizures, and eventually coma [1]. It has been associated with severe hypertension, eclampsia, but also with administration of immunosuppressants, antibodies, and other substances. In several instances, PRES has been reported after chemotherapy with [22] or without accompanying electrolyte imbalance [23]: T2-weighted MRI shows characteristic hyperintense lesions parieto-occipitally involving the gray and white matters. These signal abnormalities are transient as...
is the clinical syndrome, which usually resolves within days after cessation of therapy and symptomatic treatment of seizures and electrolytic imbalance [22].

### Cerebellar Dysfunction

Cerebellar dysfunction with dysarthria, nystagmus, and ataxia is a typical complication of cytarabine, usually at cumulative dosages > 36 g/m² [4], however, this complication has been encountered in single cases with lower dosages. Neuropathologic examination of patients coming to die with but not because of this complication showed widespread Purkinje cell loss [1]. Risk factors for the development of cerebellar dysfunction are older age, increased serum creatinine, and alkaline phosphatase [24]. The disorder is rarely accompanied by an acute encephalopathy, which is reversible after cessation of therapy. A similar cerebellar syndrome may be encountered after therapy with high-dose 5-fluorouracil, which is reversible after interruption of therapy, but may recur at drug re-exposure [1].

### Cerebral Infarctions

Single cases of cerebral ischemia after MTX, platinum-derivatives, and cyclosporine have been reported, primarily in children treated with MTX for acute leukaemia [16]. Patients receiving high doses may develop microangiopathy with calcifications in the vessel wall [16]. Thrombotic microangiopathy has been reported after exposure to mitomycin C, gemcitabine, and cyclosporine [1].

### Myelopathy

Acute myelopathy with ascending para- or tetraparesis is a rare but devastating complication of intrathecal therapy with MTX [25], Ara-C [26] or with a combination of these (“triple-therapy” with MTX, Ara-C, and steroids) [1, 25–27]. It can occur even after single-dose exposure, may involve the brainstem, as exemplified in Figure 2, may lead to a locked-in syndrome [1] or even death due to acute “encephalomyelitis” [28]. Possible risk factors are extensive meningeal disease, irradiation of the CNS, and childhood or old age [2]. The pathologic finding is that of a necrotizing myelopathy; efficient therapies have not been established. However, a recent case has been reported on a 54-year-old female with MTX-induced severe myelopathy who showed partial remission of symptoms beginning 3 days after continuous substitution of S-adenosymethionine (SAM) 3× 200 mg/die, folic acid 4×
CNS Toxicity of Chemotherapy

20 mg/die, cyanocobalamin 100 μg/die and methionine 5 g/die (iv for one week, then orally) [29]. For lack of other established treatments, substitution of these derivates of the folic acid and methionine/homocysteine metabolic pathway may be tried as well as complete CSF “exchange”.

### Others

Other neurotoxic complications of chemotherapy are listed in table 2. Five patients with capecitabine-induced multifocal leukoencephalopathy have been described with clinically and radiologically (nearly) complete resolution of signs and symptoms after discontinuation of the drug [30]. Cortical blindness may occur as an isolated symptom after cis-platinum or fludarabine administration [1]. Seizures may follow the administration of many drugs, in particular the systemic or intrathecal application of MTX [31]. Aseptic meningitis and headache affect about 10 % of patients receiving intrathecal chemotherapy [2].

### Differential Diagnosis

The diagnosis of chemotherapy-related neurotoxicity can only be established if other possible causes of neurologic dys-

---

**Table 2. Therapy/prophylaxis of chemotherapy-induced CNS toxicity**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Symptoms</th>
<th>Frequency</th>
<th>Threshold dosage</th>
<th>Risk factor</th>
<th>Therapy/prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate</td>
<td>Acute reversible encephalopathy</td>
<td>Rare</td>
<td>&gt; 0.5 g/m² (?)</td>
<td>Whole-brain radiotherapy</td>
<td>Frequently self-limiting</td>
</tr>
<tr>
<td></td>
<td>Subacute encephalopathy</td>
<td>Very rare</td>
<td>After 2nd or 3rd iv application</td>
<td>Homocystine ↑</td>
<td>Dextrometorphan (?)</td>
</tr>
<tr>
<td></td>
<td>Chronic encephalopathy</td>
<td>Infrequent</td>
<td>&gt; 0.5 g/m² (?)</td>
<td>Whole-brain radiotherapy, intrathecal MTX</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Meningitis</td>
<td>&lt; 10 %</td>
<td>Only after →</td>
<td>intrathecal application</td>
<td>Symptomatic</td>
</tr>
<tr>
<td></td>
<td>Seizures</td>
<td>Infrequent</td>
<td></td>
<td>Seizures prior to application</td>
<td>Symptomatic</td>
</tr>
<tr>
<td></td>
<td>Myelitis/myelopathy</td>
<td>Very rare</td>
<td></td>
<td>Young/old age, aggressive leukaemia, radiotherapy</td>
<td>“CSF exchange”? Multiple folate metabolites</td>
</tr>
<tr>
<td>Ara-C</td>
<td>Cerebellar dysfunction + facilitative acute encephalopathy</td>
<td>Frequent, if → cumulative dose &gt; 36 g/m²</td>
<td>Renal insufficiency, alkaline phosphatase ↑ age &gt; 60, neurological comorbidity</td>
<td>Frequently self-limiting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meningitis</td>
<td>like →</td>
<td>MTX</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Myelitis</td>
<td>like →</td>
<td>MTX</td>
<td>“CSF exchange”?</td>
<td></td>
</tr>
<tr>
<td>5-Fluorouracil</td>
<td>Acute encephalopathy</td>
<td>Rare</td>
<td>?</td>
<td>Dihydropyrimidine dehydrogenase ↓</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Cerebellar dysfunction + facilitative additional CNS symptoms</td>
<td></td>
<td>+ Allopurinol + N-Phosphonooacyt-L-aspartat (PALA) + thymidine</td>
<td>Often self-limiting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inflammatory multifocal leukoencephalopathy</td>
<td></td>
<td>+ Levamisol</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>Acute encephalopathy</td>
<td>Up to 30 %</td>
<td>?</td>
<td>High dose, renal, hepatic insufficiency, albumin ↓</td>
<td>Frequently self-limiting; methylene-blue, thiamine?</td>
</tr>
</tbody>
</table>

---

**Conflict of Interest**

The author has received honoraria from Essex-Pharma, Mundipharma, Amgen, and Sigma-Tau.
References:


